section name header

Indications ⬇

REMS

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

GI: constipation, gray-black stools/tongue, impaction (infants, debilitated patients).

Interactions ⬆ ⬇

Drug-Drug:

Availability ⬆ ⬇

(Generic available)

Route/Dosage ⬆ ⬇

US Brand Names ⬆ ⬇

Bismatrol, Peptic Relief, Pepto-Bismol

Action ⬆ ⬇

Therapeutic Effects:

Classifications ⬆ ⬇

Therapeutic Classification: antidiarrheals, antiulcer agents

Pharmacologic Classification: adsorbents

Pharmacokinetics ⬆ ⬇

Absorption: Bismuth is not absorbed; salicylate split from parent compound is >90% absorbed from the small intestine.

Distribution: Salicylate is well distributed to tissues.

Protein Binding: Bismuth and salicylate >90%.

Metabolism/Excretion: Bismuth is excreted unchanged in the feces. Salicylate undergoes extensive hepatic metabolism.

Half-life: Salicylate — 2–3 hr for low doses; 15–30 hr with larger doses.

Time/Action Profile ⬆ ⬇

(relief of diarrhea and other GI symptoms)

ROUTEONSETPEAKDURATION
POwithin 24 hrunknownunknown

Patient/Family Teaching ⬆ ⬇

Pronunciation ⬆ ⬇

BIZ-muth sub-sa-LIS-i-late

Code ⬆

NDC Code*